Conlida

Conlida (Suzhou) Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the development of long-acting injectable formulations and complex drug delivery systems. Based in Suzhou, China, the company utilizes its proprietary microsphere and nanocrystal technology platforms to create improved versions of established therapeutics, primarily targeting the 505(b)(2) regulatory pathway. Its therapeutic focus includes central nervous system disorders, metabolic diseases, and ophthalmology, with a pipeline featuring long-acting treatments for schizophrenia and Parkinson's disease. Conlida also operates as a specialized CDMO, providing high-end formulation development and manufacturing services for complex injectables to global pharmaceutical partners. The company is backed by prominent venture capital firms and aims to improve patient compliance through its advanced delivery technologies.